Volume 3 Issue 1

Volume 3 Issue 1

_____________________________________________________________________________________________________

Short Commentary
Hypothesizing Benefits of the Incorporation of Genetic Addiction Risk Score (GARSRX™Rx™) and Dopamine Agonist Modalities (DAM) in Clinical Addiction Medicine.

K. Blum, PhD, DE. Smith, MD, J. Femino, MD, AK.Roy, MD, T. Simpatico, MD, D. Inaba, Pharm D., G. Agan,BSc., JL.Fratantonio, Pharm D., M. Febo,PhD, F Fornari, PhD, M Hauser, MSc, D. Barh, PhD

We have entered the genomics era with hope for the future of medicine including Psychiatry. Understanding the role of DNA and polymorphic associations with brain reward circuitry has led to a new understanding of all addictive behaviors. We present here, a brief review of the role of both neurogentics and nutrigenomics as cornerstones that link more accurate genetic diagnosis and Dopamine D2 agonist therapy to induce dopaminergic activation.

Full textDownload PDF     

_____________________________________________________________________________________________________

Research Article
15 Hz Repetitive Transcranial Magnetic Stimulation Over the Left Prefrontal Cortex Reduces Cocaine Craving

Ernestina Politi MD, PhD, Giampiero Bottero MD, Eugenia Fauci MD, Valentina Ferrari MD, Enrico Smeraldi MD

Recent studies support the association between addiction and the progressive alteration of cortical excitability, particularly focussing on the effect of chronic assumption of substance of abuse over the prefrontal cortex through the use of both cerebral stimulation and electroencephalographic techniques.

Full textDownload PDF